Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Project Updates and Milestones news
21 April 2026
Merck and Eisai: LITESPARK‑012 triplet regimens fail to improve PFS and OS versus KEYTRUDA+LENVIMA in first‑line RCC
Phase 3 LITESPARK‑012 tested pembrolizumab+lenvatinib+belzutifan and a pembrolizumab+quavonlimab+lenvatinib regimen; safety profiles consistent with prior studies; full analysis ongoing.
21 April 2026
Siemens expands Industrial Edge for enhanced data and AI integration
Industrial Edge: AI Suite & WinCC Unified GA. Management adds IEC62443 security and air‑gap. Information Hub gets bidirectional sync and ARM support. New machine‑vision and rugged HW partners.
21 April 2026
Arkema at Chinaplas 2026: high-performance materials
Showcases bio-based, recyclable high-performance polymers, additives and advanced materials for mobility, electronics, semiconductors and consumer goods; highlights Asia production expansions.
21 April 2026
LANXESS at IFAT 2026: Filtration for PFAS, Phosphorus, Micropollutants and UPW
IFAT showcase: ion‑exchange resins and adsorbents for regenerable phosphorus removal (Bayoxide E IN 20), PFAS and fluoride (MDS/TP resins), micropollutants (VP OC), and the LewaPlus design tool.
21 April 2026
Evonik opens expanded specialty-amine plant in Nanjing
Double-digit-million-euro expansion boosts specialty amine capacity in Nanjing, improving supply security, raw-material access and low-VOC additives for polyurethane/epoxy; plant runs on green power
21 April 2026
Evonik commissions 150 kV Antwerp substation
New 150 kV substation in Antwerp replaces 36 kV link, boosting capacity for industrial electrification and CO2 cuts; built with Elia, includes two 150t transformers and 6 ~1km cables.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
21 April 2026
Statkraft completes Montes de Cierzo repowering with 98% waste recovery
44 ageing turbines replaced by 10 new units; capacity rises from 60 to 90 MW and output to 300 GWh/yr. 14.26 MW (28.51 MWh) batteries added. €5M local co-investment; full repower by 2027.
21 April 2026
ScottishPower and Masdar install UK’s largest 115m blades at East Anglia THREE
First turbine installed; 95×14MW units (1.4GW) with UK-made blades (285 in Hull). 262m tip height; will power ~1.3M homes. Installation using two jack‑up vessels.
21 April 2026
LKAB advances Luleå critical‑minerals demonstration plant
Installation underway at demo facility; building complete, commissioning autumn. Malmberget pilot tests the chain. Tech will extract phosphorus and 17 REEs from iron‑ore residues; permits ongoing.
21 April 2026
Axens, IFPEN and JEPLAN validate industrial-scale textile-to-textile polyester recycling
Semi-industrial test processed tens of tons of post-consumer polyester textiles to produce BHET monomer, validating textile-to-textile chemical recycling and enabling circular polyester loops.
21 April 2026
FDA accepts Roche sBLA for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE)
ALLEGORY phase III: SRI‑4 response 76.7% vs 53.5% (adj diff 23.1%), doubled remission rates, fewer flares and reduced steroid use. FDA decision expected by Dec 2026.
21 April 2026
China Petrochemical’s next-generation green intelligent aromatics technology achieves international leading status
New aromatics tech validated: p-xylene adsorbent, ethylbenzene‑conversion isomerization catalyst, SMB single‑tower separation, intelligent control; 25 patents; +50% low‑temp heat reuse, −27% energy/unit
20 April 2026
FDA Accepts Genentech sBLA for Gazyva in SLE
FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.
20 April 2026
Topsoe to supply HydroFlex for Abundia's plastic-to-fuel facilities
Selected tech will convert plastic waste into drop-in diesel, sustainable aviation fuel and chemical feedstock at three North American plants (1,500 bpd each). Baytown FID end-2026; ops 2029.
20 April 2026
Elkem sells Saguenay biocarbon unit to CHAR Tech, secures 5‑year 62,500‑t supply
Sale transfers pilot/demo facility and proprietary pellet tech; site to be upgraded to 15,000 t/yr of pellets, converting raw biochar into biocarbon for ferrosilicon decarbonisation and smelter supply.
20 April 2026
Honeywell to support Dangote’s petrochemical expansion
Provide Oleflex tech to add 750,000 tpy propylene and petrochemical catalysts to produce 400,000 tpy linear alkylbenzene, boosting regional supply chains and industrial growth.
20 April 2026
Merck: FDA grants priority review for KEYTRUDA/KEYTRUDA QLEX with Padcev in cisplatin‑eligible MIBC
FDA granted priority review for two sBLAs after Phase 3 KEYNOTE‑B15 showed EFS and OS benefit; PDUFA Aug 17, 2026. If approved, first perioperative options for MIBC regardless of cisplatin eligibility.
20 April 2026
Perpetual Next hires GLS for U.S. biomethanol site selection
Consultant to assess U.S. candidate sites and feedstock markets, compare torrefaction, biomethanol and integrated concepts, and deliver evidence-based site-selection reports with risks and next steps.
20 April 2026
Novo Nordisk: Etavopivat meets phase‑3 HIBISCUS endpoints — reduces VOCs and increases haemoglobin in sickle cell disease
HIBISCUS phase‑3 (n=385, ≥12 yrs): etavopivat cut VOCs by 27% and delayed first VOC ~4 months; 48.7% had >1 g/dL Hb rise at 24 weeks vs 7.2% placebo. Well tolerated; filing H2 2026.
20 April 2026
PPG installs radiation-curing test line in Marly, France
New Marly R&D line tests IR, UV (LED, excimer, arc) and EB curing to replicate production, speed development, cut customer trials, and reduce energy use and VOCs.
20 April 2026
Asahi Kasei launches Phase I trial of AK1940 for autoimmune diseases
Peptide-based TNFR1 antagonist discovered with PeptiDream showed activity in animal models; Japan trial began Apr 19 to evaluate PK, safety and tolerability of subcutaneous doses in healthy volunteers
20 April 2026
GSK's Blenrep approved in China for 2L+ relapsed/refractory multiple myeloma
Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.
20 April 2026
thyssenkrupp Uhde wins FEED for Brunei Fertilizer Industries ammonia export expansion
Designs cryogenic ammonia tank, jetty, pipelines and ship‑loading systems for large‑scale exports; integrates with existing complex to enable safe, reliable operations and new market access.
20 April 2026
Eni’s Geliga‑1 Giant Gas Discovery in Indonesia’s Kutei Basin — ≈5 Tcf gas, 300 MMbbl condensate
Geliga‑1 hit a high‑quality Miocene gas column; DST planned. Discovery bolsters basin scale, may enable a fast‑track third production hub by tying into nearby Gula and existing infrastructure
20 April 2026
Siemens launches Eigen Engineering Agent for autonomous industrial engineering
Moves industrial AI from assistance to autonomous execution—plans, codes, configures and validates systems. Pilots report 2–5× faster delivery, up to 50% efficiency gains and higher solution quality.
17 April 2026
EMA recommends Nobivac NXT HCPChFeLV, EU’s first self‑amplifying RNA cat vaccine
Protects cats vs five pathogens (herpes, calici, panleuk, FeLV, Chlamydia). Trials show adequate immunity, reduced disease/shedding; 1–3 yr protection; well tolerated.
17 April 2026
European Commission approves Merck’s ENFLONSIA for infant RSV prevention
Single 105 mg IM, non-weight-based dose gives ~5 months' RSV protection; trials showed ~60% fewer medically attended LRIs and ~84% fewer RSV hospitalizations; safety similar to placebo
16 April 2026
Repsol to raise oil production in Venezuela
Agreed with Venezuela and PDVSA to resume Petroquiriquire operations, ensure payments and raise output 50% in 12 months and 3x in 3 years if conditions hold; OFAC GL50A permits transactions.
16 April 2026
Siemens tests Humanoid HMND 01 powered by NVIDIA physical AI
a wheeled humanoid robot was trialed in an electronics factory, autonomously moving totes, 60 moves/hour, >8h uptime, >90% pick success. Simulation-first AI cut prototype time from 18-24 to 7 months.
16 April 2026
Lilly ACHIEVE‑4 confirms Foundayo cardiovascular safety and cardiometabolic benefits
ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.
Next →
